Searched for
SUN PHARMA GUIDANCE
Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Buy capital goods on dips, stay cautious on IT and consumption: Sudip BandyopadhyayMarket expert Sudip Bandyopadhyay outlines investment strategies across key sectors. He sees opportunities in State Bank of India and a gen...
- Sensex falls 114 points, Nifty closes below 24,350; broader markets outperformIndian stock markets surged on Thursday, with Sensex and Nifty extending gains for a second day. This rise was fueled by optimism over a po...
- Why market fell today? Sensex slumps 583 pts, Nifty below 24,000; 7 key triggersIndian stock markets experienced a significant downturn on Thursday, with Sensex and Nifty both falling over 0.7%. This decline was driven ...
- Stock picking key as auto, banks face near-term headwinds: Sandip SabharwalMarket expert Sandip Sabharwal maintains a constructive long-term outlook but stresses selectivity due to near-term risks like rising input...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- No Sun signs for investors, stock likely to stay underperformerThe management has broken with the tradition of providing guidance for the fiscal year
- A bear phase for pharma pack! 10 stocks fall up to 40% from highsNifty Pharma index is down over 20% from its 52-week high of 13,753.50, which indicates a bearish phase for the index. Glenmark, Cipla are ...
- Sun Pharma a good buy at current level, near-term concerns remain: Rahul Shah, Motilal Oswal Financial SecuritiesRahul Shah, Associate VP, Motilal Oswal Financial Securities, gives his take on the market post the Sun Pharma guidance and Infosys results.
- Shares of Sun Pharma dips 15% after profit warning triggers downgradesShares of India’s largest pharmaceutical company Sun Pharma slumped 15% to Rs 805 on Tuesday—its biggest single-day dropever—after profit w...
- Jefferies maintains buy call on Sun pharma despite adverse guidanceJefferies said it is positive about Sun Pharma's strong key fundamentals, though its stock plunged 15 per cent today.
- Sun Pharma shares gain on strong guidance for doxycyclineSun Pharmaceutical went up 1% after a competitor raised its revenue guidance, citing strong sale of a generic antibiotic also sold by Sun P...
- CLSA sees over 20% upside in Sun Pharma post Q4 resultsCLSA has maintained ‘buy’ rating on Sun Pharma with a price target of Rs 1220 per share, the Asian focused broker said in a report.
- Brokers' call: Sun Pharma remains a buyMorgan Stanley has maintained a ‘Buy’ rating on Sun Pharmaceuticals with an ‘Overweight’ rating with a target price of Rs 1,159.
- What Does Sun Pharma's September Quarter Performance Indicate?With Caraco resuming manufacturing at its facilities in Michigan, the company is likely to gradually recover any loss in revenues.
- Brokers' call on Jaiprakash Associates, Sun Pharma, RECMorgan Stanley has assigned an ‘Overweight’ rating to Jaiprakash Associates on the back of a possible reduction in debt and higher margins ...
- Sun Pharma to invest Rs 450 crore for capacity expansion in FY-12Sun Pharmaceutical Industries today said it plans to invest Rs 450 crore for capacity expansion and upgradation of existing plants
Load More
